Which has preferable earnings and valuation, OXB or GNS?

Genus has higher revenue and earnings than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oxford Biomedica £168.74M 3.43 -£143.51M -£26.92 N/A Genus £672M 2.29 £7.87M £71.00 32.65

Is OXB or GNS more profitable?

Genus has a net margin of 7.07% compared to Oxford Biomedica's net margin of -17.85%. Genus' return on equity of 9.70% beat Oxford Biomedica's return on equity. Company Net Margins Return on Equity Return on Assets Oxford Biomedica -17.85% -48.56% -12.67% Genus 7.07% 9.70% 3.31%

Do analysts recommend OXB or ERGO?

Oxford Biomedica presently has a consensus price target of GBX 621.85, suggesting a potential upside of 29.96%. Given Oxford Biomedica's stronger consensus rating and higher probable upside, equities research analysts clearly believe Oxford Biomedica is more favorable than Ergomed. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oxford Biomedica 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Ergomed 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is OXB or ERGO more profitable?

Ergomed has a net margin of 9.87% compared to Oxford Biomedica's net margin of -17.85%. Ergomed's return on equity of 18.08% beat Oxford Biomedica's return on equity. Company Net Margins Return on Equity Return on Assets Oxford Biomedica -17.85% -48.56% -12.67% Ergomed 9.87% 18.08% 10.16%

Do analysts rate OXB or SLN?

Oxford Biomedica presently has a consensus price target of GBX 621.85, suggesting a potential upside of 29.96%. Given Oxford Biomedica's stronger consensus rating and higher probable upside, equities research analysts clearly believe Oxford Biomedica is more favorable than Silence Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oxford Biomedica 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Silence Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media refer more to AVCT or OXB?

In the previous week, Oxford Biomedica had 1 more articles in the media than Avacta Group. MarketBeat recorded 2 mentions for Oxford Biomedica and 1 mentions for Avacta Group. Avacta Group's average media sentiment score of 0.67 beat Oxford Biomedica's score of 0.55 indicating that Avacta Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avacta Group 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oxford Biomedica 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Oxford Biomedica (OXB) Competitors

GBX 478.50 -26.50 (-5.25%)

As of 08/10/2026 12:17 PM Eastern

Compare

OXB vs. GNS, ONT, ERGO, SLN, and AVCT

Should you buy Oxford Biomedica stock or one of its competitors? Oxford Biomedica's main competitors and comparable companies include Genus (GNS), Oxford Nanopore Technologies (ONT), Ergomed (ERGO), Silence Therapeutics (SLN), and Avacta Group (AVCT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Oxford Biomedica compare to Genus?

Oxford Biomedica (LON:OXB) and Genus (LON:GNS) are related small-cap companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations.

Genus has a net margin of 7.07% compared to Oxford Biomedica's net margin of -17.85%. Genus' return on equity of 9.70% beat Oxford Biomedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oxford Biomedica	-17.85%	-48.56%	-12.67%
Genus	7.07%	9.70%	3.31%

32.4% of Oxford Biomedica shares are owned by institutional investors. Comparatively, 51.9% of Genus shares are owned by institutional investors. 25.8% of Oxford Biomedica shares are owned by company insiders. Comparatively, 0.7% of Genus shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Oxford Biomedica has a beta of 1.1, meaning that its stock price is 10% more volatile than the broader market. Comparatively, Genus has a beta of 0.901, meaning that its stock price is 10% less volatile than the broader market.

Genus has higher revenue and earnings than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oxford Biomedica	£168.74M	3.43	-£143.51M	-£26.92	N/A
Genus	£672M	2.29	£7.87M	£71.00	32.65

Oxford Biomedica presently has a consensus price target of GBX 621.85, indicating a potential upside of 29.96%. Genus has a consensus price target of GBX 3,216.67, indicating a potential upside of 38.77%. Given Genus' higher probable upside, analysts plainly believe Genus is more favorable than Oxford Biomedica.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oxford Biomedica	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Genus	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Oxford Biomedica had 2 more articles in the media than Genus. MarketBeat recorded 2 mentions for Oxford Biomedica and 0 mentions for Genus. Genus' average media sentiment score of 1.11 beat Oxford Biomedica's score of 0.55 indicating that Genus is being referred to more favorably in the news media.

Company	Overall Sentiment
Oxford Biomedica	Positive
Genus	Positive

Summary

Genus beats Oxford Biomedica on 10 of the 15 factors compared between the two stocks.

How does Oxford Biomedica compare to Oxford Nanopore Technologies?

Oxford Nanopore Technologies (LON:ONT) and Oxford Biomedica (LON:OXB) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment and analyst recommendations.

18.3% of Oxford Nanopore Technologies shares are held by institutional investors. Comparatively, 32.4% of Oxford Biomedica shares are held by institutional investors. 2.5% of Oxford Nanopore Technologies shares are held by insiders. Comparatively, 25.8% of Oxford Biomedica shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Oxford Nanopore Technologies has a beta of 0.92, suggesting that its stock price is 8% less volatile than the broader market. Comparatively, Oxford Biomedica has a beta of 1.1, suggesting that its stock price is 10% more volatile than the broader market.

In the previous week, Oxford Biomedica had 2 more articles in the media than Oxford Nanopore Technologies. MarketBeat recorded 2 mentions for Oxford Biomedica and 0 mentions for Oxford Nanopore Technologies. Oxford Nanopore Technologies' average media sentiment score of 1.50 beat Oxford Biomedica's score of 0.55 indicating that Oxford Nanopore Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
Oxford Nanopore Technologies	Positive
Oxford Biomedica	Positive

Oxford Biomedica has a net margin of -17.85% compared to Oxford Nanopore Technologies' net margin of -64.85%. Oxford Nanopore Technologies' return on equity of -29.43% beat Oxford Biomedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oxford Nanopore Technologies	-64.85%	-29.43%	-14.42%
Oxford Biomedica	-17.85%	-48.56%	-12.67%

Oxford Biomedica has lower revenue, but higher earnings than Oxford Nanopore Technologies. Oxford Biomedica is trading at a lower price-to-earnings ratio than Oxford Nanopore Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oxford Nanopore Technologies	£223.90M	5.61	-£175.21M	-£15.10	N/A
Oxford Biomedica	£168.74M	3.43	-£143.51M	-£26.92	N/A

Oxford Nanopore Technologies presently has a consensus target price of GBX 205.75, indicating a potential upside of 59.62%. Oxford Biomedica has a consensus target price of GBX 621.85, indicating a potential upside of 29.96%. Given Oxford Nanopore Technologies' higher possible upside, research analysts clearly believe Oxford Nanopore Technologies is more favorable than Oxford Biomedica.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oxford Nanopore Technologies	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Oxford Biomedica	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Oxford Biomedica beats Oxford Nanopore Technologies on 9 of the 16 factors compared between the two stocks.

How does Oxford Biomedica compare to Ergomed?

Oxford Biomedica (LON:OXB) and Ergomed (LON:ERGO) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, media sentiment, valuation, risk and dividends.

In the previous week, Oxford Biomedica had 2 more articles in the media than Ergomed. MarketBeat recorded 2 mentions for Oxford Biomedica and 0 mentions for Ergomed. Oxford Biomedica's average media sentiment score of 0.55 beat Ergomed's score of 0.00 indicating that Oxford Biomedica is being referred to more favorably in the media.

Company	Overall Sentiment
Oxford Biomedica	Positive
Ergomed	Neutral

32.4% of Oxford Biomedica shares are owned by institutional investors. Comparatively, 71.1% of Ergomed shares are owned by institutional investors. 25.8% of Oxford Biomedica shares are owned by insiders. Comparatively, 18.2% of Ergomed shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Oxford Biomedica presently has a consensus price target of GBX 621.85, suggesting a potential upside of 29.96%. Given Oxford Biomedica's stronger consensus rating and higher probable upside, equities research analysts clearly believe Oxford Biomedica is more favorable than Ergomed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oxford Biomedica	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Ergomed	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Oxford Biomedica has a beta of 1.1, indicating that its stock price is 10% more volatile than the broader market. Comparatively, Ergomed has a beta of 0.79, indicating that its stock price is 21% less volatile than the broader market.

Ergomed has lower revenue, but higher earnings than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than Ergomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oxford Biomedica	£168.74M	3.43	-£143.51M	-£26.92	N/A
Ergomed	£152.09M	0.00	£15M	£0.29	N/A

Ergomed has a net margin of 9.87% compared to Oxford Biomedica's net margin of -17.85%. Ergomed's return on equity of 18.08% beat Oxford Biomedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oxford Biomedica	-17.85%	-48.56%	-12.67%
Ergomed	9.87%	18.08%	10.16%

Summary

Oxford Biomedica beats Ergomed on 8 of the 15 factors compared between the two stocks.

How does Oxford Biomedica compare to Silence Therapeutics?

Oxford Biomedica (LON:OXB) and Silence Therapeutics (LON:SLN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, dividends and earnings.

Silence Therapeutics has a net margin of 0.00% compared to Oxford Biomedica's net margin of -17.85%. Silence Therapeutics' return on equity of 0.00% beat Oxford Biomedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oxford Biomedica	-17.85%	-48.56%	-12.67%
Silence Therapeutics	N/A	N/A	N/A

Silence Therapeutics has lower revenue, but higher earnings than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oxford Biomedica	£168.74M	3.43	-£143.51M	-£26.92	N/A
Silence Therapeutics	£11.35M	0.00	N/A	-£48.60	N/A

32.4% of Oxford Biomedica shares are held by institutional investors. 25.8% of Oxford Biomedica shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oxford Biomedica	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Silence Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Oxford Biomedica had 2 more articles in the media than Silence Therapeutics. MarketBeat recorded 2 mentions for Oxford Biomedica and 0 mentions for Silence Therapeutics. Oxford Biomedica's average media sentiment score of 0.55 beat Silence Therapeutics' score of 0.00 indicating that Oxford Biomedica is being referred to more favorably in the media.

Company	Overall Sentiment
Oxford Biomedica	Positive
Silence Therapeutics	Neutral

Summary

Oxford Biomedica beats Silence Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Oxford Biomedica compare to Avacta Group?

Avacta Group (LON:AVCT) and Oxford Biomedica (LON:OXB) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, media sentiment, dividends, profitability and analyst recommendations.

Avacta Group presently has a consensus price target of GBX 99, indicating a potential upside of 53.78%. Oxford Biomedica has a consensus price target of GBX 621.85, indicating a potential upside of 29.96%. Given Avacta Group's higher probable upside, research analysts clearly believe Avacta Group is more favorable than Oxford Biomedica.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avacta Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Oxford Biomedica	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Oxford Biomedica had 1 more articles in the media than Avacta Group. MarketBeat recorded 2 mentions for Oxford Biomedica and 1 mentions for Avacta Group. Avacta Group's average media sentiment score of 0.67 beat Oxford Biomedica's score of 0.55 indicating that Avacta Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avacta Group	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oxford Biomedica	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Avacta Group has a beta of 1.12, meaning that its stock price is 12% more volatile than the broader market. Comparatively, Oxford Biomedica has a beta of 1.1, meaning that its stock price is 10% more volatile than the broader market.

3.1% of Avacta Group shares are held by institutional investors. Comparatively, 32.4% of Oxford Biomedica shares are held by institutional investors. 47.7% of Avacta Group shares are held by company insiders. Comparatively, 25.8% of Oxford Biomedica shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Oxford Biomedica has a net margin of -17.85% compared to Avacta Group's net margin of -33,961.06%. Oxford Biomedica's return on equity of -48.56% beat Avacta Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avacta Group	-33,961.06%	-2,929.47%	-21.80%
Oxford Biomedica	-17.85%	-48.56%	-12.67%

Avacta Group has higher earnings, but lower revenue than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than Avacta Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avacta Group	£113K	2,669.36	-£30.08M	-£9.66	N/A
Oxford Biomedica	£168.74M	3.43	-£143.51M	-£26.92	N/A

Summary

Avacta Group beats Oxford Biomedica on 8 of the 15 factors compared between the two stocks.

Get Oxford Biomedica News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OXB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OXB vs. The Competition

Export

Metric	Oxford Biomedica	Biotechnology Industry	Healthcare Sector	LON Exchange
Market Cap	£579.16M	£3.70B	£7.02B	£2.89B
Dividend Yield	4.57%	3.76%	2.58%	6.09%
P/E Ratio	-17.77	9.09	269.19	368.30
Price / Sales	3.43	1,255.18	588.76	83,647.95
Price / Cash	3.01	44.95	28.89	27.89
Price / Book	7.07	17.66	11.27	7.22
Net Income	-£143.51M	-£13.25M	£3.45B	£5.89B
7 Day Performance	-15.46%	3.11%	1.92%	1.30%
1 Month Performance	-21.69%	-1.68%	-0.58%	2.23%
1 Year Performance	11.09%	61.75%	75.49%	73.70%

Oxford Biomedica Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OXB Oxford Biomedica	2.7271 of 5 stars	GBX 478.50 -5.2%	GBX 621.85 +30.0%	+8.6%	£579.16M	£168.74M	N/A	891	Analyst Forecast High Trading Volume
GNS Genus	3.9628 of 5 stars	GBX 2,244 +0.8%	GBX 3,216.67 +43.3%	-8.0%	£1.49B	£672M	31.61	480
ONT Oxford Nanopore Technologies	3.5853 of 5 stars	GBX 113.90 +1.3%	GBX 212.60 +86.7%	-39.9%	£1.11B	£223.90M	N/A	1,281
ERGO Ergomed	N/A	N/A	N/A	N/A	£701.00M	£152.09M	4,641.38	6
SLN Silence Therapeutics	N/A	N/A	N/A	N/A	£480.35M	£11.35M	N/A	100	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:OXB) was last updated on 8/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oxford Biomedica (OXB) Competitors

OXB vs. GNS, ONT, ERGO, SLN, and AVCT

How does Oxford Biomedica compare to Genus?

Summary

How does Oxford Biomedica compare to Oxford Nanopore Technologies?

Summary

How does Oxford Biomedica compare to Ergomed?

Summary

How does Oxford Biomedica compare to Silence Therapeutics?

Summary

How does Oxford Biomedica compare to Avacta Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OXB vs. The Competition

Oxford Biomedica Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oxford Biomedica (OXB) Competitors

OXB vs. GNS, ONT, ERGO, SLN, and AVCT

How does Oxford Biomedica compare to Genus?

Is OXB or GNS more profitable?

Do insiders and institutionals believe in OXB or GNS?

Which has more risk and volatility, OXB or GNS?

Which has preferable earnings and valuation, OXB or GNS?

Do analysts rate OXB or GNS?

Does the media favor OXB or GNS?

Summary

How does Oxford Biomedica compare to Oxford Nanopore Technologies?

Do institutionals & insiders believe in ONT or OXB?

Which has more risk and volatility, ONT or OXB?

Does the media favor ONT or OXB?

Is ONT or OXB more profitable?

Which has better valuation & earnings, ONT or OXB?

Do analysts recommend ONT or OXB?

Summary

How does Oxford Biomedica compare to Ergomed?

Does the media prefer OXB or ERGO?

Do insiders & institutionals have more ownership in OXB or ERGO?

Do analysts recommend OXB or ERGO?

Which has more volatility and risk, OXB or ERGO?

Which has stronger valuation and earnings, OXB or ERGO?

Is OXB or ERGO more profitable?

Summary

How does Oxford Biomedica compare to Silence Therapeutics?

Is OXB or SLN more profitable?

Which has better valuation & earnings, OXB or SLN?

Do institutionals & insiders hold more shares of OXB or SLN?

Do analysts rate OXB or SLN?

Does the media prefer OXB or SLN?

Summary

How does Oxford Biomedica compare to Avacta Group?

Do analysts prefer AVCT or OXB?

Does the media refer more to AVCT or OXB?

Which has more volatility and risk, AVCT or OXB?

Do institutionals and insiders believe in AVCT or OXB?

Is AVCT or OXB more profitable?

Which has higher earnings and valuation, AVCT or OXB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OXB vs. The Competition

Oxford Biomedica Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools